Skip to content

LNK in Polycystic Ovary Syndrome With Insulin Resistance

LNK Participates in Insulin Resistance in Polycystic Ovary Syndrome by Regulating Adipose Glucose Transport

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05146063
Enrollment
80
Registered
2021-12-06
Start date
2021-11-05
Completion date
2023-12-31
Last updated
2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Polycystic Ovarian Syndrome

Brief summary

Insulin resistance (IR) is an important pathological feature of polycystic ovary syndrome (PCOS), with an incidence rate of up to 85%, which seriously affects the patient's fertility, quality of life, and offspring health, but the mechanism is unknown. The adaptor protein LNK is closely related to metabolic diseases. Our exome sequencing has found that the mutation rate of LNK gene in patients with PCOS and IR is high. Studies have found that LNK can affect adipose inflammation and impair glucose tolerance. Whether LNK is related to fat metabolism is worth further study. Our previous research found that: LNK expression was significantly increased in adipose tissue of patients with PCOS and IR. Knockout of LNK in PCOS IR model mice can reduce serum triglycerides, free fatty acids, high-sensitivity C-reactive protein levels and reduce fatty liver occurrence, which indicates that LNK has a mitigating effect on IR. Mechanism studies have shown that LNK knockout can upregulate the glucose transporter Glut4, also LNK and insulin receptor substrate IRS-1 can form protein complexes. Based on the above research basis, we propose the following scientific hypothesis: LNK in adipose tissue can regulate insulin signaling pathway by binding to IRS-1, downregulate Glut4, and participate in PCOS IR occurrence. This project intends to clarify the specific mechanism by which LNK regulates glucose transport and participate in IR in combination with clinical specimens, animal models and cell experiments, and provide scientific basis for LNK as a potential therapeutic target for PCOS IR.

Interventions

DIAGNOSTIC_TESTTake the patient's subcutaneous fat tissue to detect the expression of LNK

Take the patient's subcutaneous fat tissue to detect the mRNA and protein expression levels of LNK by RT-qPCR and western blot.

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Patients with polycystic ovary syndrome who meet the 2003 Rotterdam criteria

Exclusion criteria

* Do not meet the diagnostic criteria for polycystic ovary syndrome

Design outcomes

Primary

MeasureTime frameDescription
mRNA expression levels of LNK2 yearsThe expression level of LNK mRNA in the subcutaneous adipose tissue of the PCOS patients
protein expression levels of LNK2 yearsThe expression level of LNK protein in the subcutaneous adipose tissue of the PCOS patients

Countries

China

Contacts

Primary ContactYi Zhang
sys_iit@163.com+862081332120

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026